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Alternative Splicing of Agrin
Alters Its Binding to Heparin, Dystroglycan,
and the Putative Agrin Receptor
Matthias Gesemann,* Valeria Cavalli,* Alain J. Denzer,* Denzer et al., 1995). AChR-aggregating activity is con-
Andrea Brancaccio,² Beat Schumacher,* fined to a 95 kDa C-terminal fragment (Nitkin et al., 1987;
and Markus A. Ruegg* Tsim et al., 1992; Ferns et al., 1993), and further,
*Department of Pharmacology N-terminal deletions in rat and chick agrin have revealed
²Department of Biophysical Chemistry that a 45 kDa C-terminal fragment has similar activity
Biozentrum (Hoch et al., 1994; Gesemann et al., 1995). Within this
University of Basel fragment, two sites are modified by alternative mRNA
CH-4056 Basel splicing (Ruegg et al., 1992; Rupp et al., 1992; McMahan
Switzerland et al., 1992; Thomas et al., 1993). The sequence of insert
A (called y in rat), Lys-Ser-Arg-Lys, is identical in agrin
of the marine ray, chicken, rat, and mouse (Rupp et al.,
1991, 1992; Tsim et al., 1992; Smith et al., 1992). Inserts
Summary
at site B (called z in rat) of 8, 11, or 19 (8 1 11) amino
acid length are less well conserved (5 identical residuesAgrin is a heparan sulfate proteoglycan that induces
in the 8 amino acid insert; 3 identical residues in the 11aggregation of acetylcholine receptors (AChRs) at the
amino acid insert). The sequence of these inserts affectsneuromuscular synapse. This aggregating activity is
the AChR-aggregating activity of agrin: while recombi-modulated by alternative splicing. Here, we compared
nant rat, chick, and ray agrinA4B8 (4 amino acids at sitebinding of agrin isoforms to heparin, a-dystroglycan,
A; 8 amino acids at site B) induces AChR aggregation atand cultured myotubes. We find that the alternatively
picomolar concentrations, no activity of soluble agrinA0B0spliced 4 amino acid insert (KSRK) is required for hep-
(no inserts at either site) is detected (Ferns et al., 1993;arin binding. The binding affinity of agrin isoforms to
Gesemann et al., 1995).a-dystroglycan correlates neither with binding to hep-
The 95 kDa fragment of agrin contains three domainsarin nor with their AChR-aggregating activities. More-
homologous to the globular (G) domains originally de-over, the minimal fragment sufficient to induce AChR
scribed in the a chains of laminin (Sasaki et al., 1988;aggregation does not bind to a-dystroglycan. Never-
see Figure 1). G domains of laminin confer binding totheless, this fragment still binds to cultured muscle
heparin, integrins, and the recently described noninte-cells. Its binding is competed only by agrin isoforms
grin receptor a-dystroglycan, a peripheral membranethat are active in AChR aggregation, and therefore this
protein of the dystrophin±glycoprotein complex (DGC;binding site is likely to represent the receptor that
Yurchenco et al., 1993; Gee et al., 1993). Several linesinitiates AChR clustering.
of evidence suggest that this DGC links the subsarco-
lemmal cytoskeleton of the muscle fibers to the basal
Introduction lamina to confer physical stability during contraction. As
a consequence, disruption of any of these components
The induction of synaptic specializations requires a local leads to muscular dystrophy (for review see Campbell,
exchange of signals between pre- and postsynaptic 1995).
cells. A widely used model to study the process of syn- The presence of G domains in agrin prompted Carbo-
apse formation is the synapse between motor neurons netto and colleagues to investigate binding of rat ag-
and muscle cells, the neuromuscular junction (NMJ; for rinA4B8 to a-dystroglycan. They found that a 100 kDareview see Hall and Sanes, 1993). The earliest sign of
C-terminal fragment bound to native and denatured
postsynaptic specialization in muscle cells is the aggre-
a-dystroglycan (Gee et al., 1994). Similar experiments
gation of acetylcholine receptors (AChRs). This event is
of Campanelli et al. (1994) and Sugiyama et al. (1994)initiated by factors released from the nerve terminals of
have confirmed this. With an independent approach,motor neurons (Frank and Fischbach, 1979). Several
Bowe et al. (1994) found that agrin binds to dystroglycanlines of evidence suggest that this factor is agrin (Reist
from the electric organ of Torpedo californica. Hence,et al., 1992; Cohen and Godfrey, 1992). When added to
there is now strong evidence that a-dystroglycan is thecultured muscle cells, agrin induces the aggregation
major binding protein of agrin in muscle cells.of AChRs and several additional components that are
The functional role of the binding of agrin to a-dystro-concentrated at the NMJ in vivo (Nitkin et al., 1987;
glycan in AChR aggregation, however, is still unclear.Wallace, 1989; Nitkin and Rothschild, 1990). The cluster-
The finding that both binding of agrin to a-dystroglycaning of AChRs is preceded by tyrosine phosphorylation
and AChR aggregation are Ca21 dependent and are in-of their b subunits (Wallace et al., 1991) and is abolished
hibited by heparin (Wallace, 1990; Bowe et al., 1994;by inhibitors that affect the state of phosphorylation
Campanelli et al., 1994; Gee et al., 1994; Sugiyama et(Wallace, 1994, 1995; Meier et al., 1995). This is consis-
al., 1994) provided circumstantial evidence thattent with the idea that agrin-induced AChR clustering is
a-dystroglycan may be the receptor mediating AChRmediated by a muscle cell receptor that activates an
aggregation. However, attempts to perturb agrin-in-intracellular signaling cascade (McMahan, 1990).
duced AChR aggregation by monoclonal antibody (MAb)Chick agrin is a heparan sulfate proteoglycan (HSPG)
with an apparent Mr of 400±600 kDa (Tsen et al., 1995; IIH6, which is directed against a-dystroglycan and
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Figure 1. Structural Domains of Chick Agrin
and of Fragments Used in This Study
Domains, potential sites for N-glycosylation,
and glycosaminoglycan side chain attach-
ment are shown. Location of alternatively
spliced sites, including their amino acid se-
quences, are shown. Names of agrin frag-
ments used in this study are given. As a help,
the previously described construct c45A4B8
(stippled) is included.
blocks binding of agrin, have produced conflicting re- lower affinity. Binding of agrin to a-dystroglycan is not
sults: while Gee et al. (1994) observed inhibition of agrin- required for AChR aggregation, since the minimal frag-
induced AChR clustering, Campanelli et al. (1994) re- ment sufficient for AChR aggregation, c21B8, does not
ported an effect on the shape of, rather than the number bind to a-dystroglycan. Nevertheless, this fragment
of, AChR clusters, and Sugiyama et al. (1994) did not binds to some other site on muscle cells. From this, we
see any effects (see also Sealock and Froehner, 1994; conclude that AChR aggregation is mediated by the
Fallon and Hall, 1994). Moreover, Sugiyama et al. (1994) binding of active agrin to a novel muscle cell receptor.
observed that agrin isoforms, irrespective of their ability
to induce AChR clusters, bound a-dystroglycan with
Resultssimilar affinities. It is therefore unlikely that binding of
agrin to a-dystroglycan is sufficient to initiate AChR ag-
For our studies, we generated cDNA constructs of differ-gregation.
ent lengths as depicted in Figure 1. Recombinant pro-We recently found that a 21 kDa fragment containing
teins were produced in eukaryotic COS7 or 293 cellsonly site B8 and the most C-terminal G domain (c21B8;
and subsequently purified by immunoaffinity columnssee Figure 1) is sufficient to induce AChR aggregation
using MAb 5B1 (Reist et al., 1987; Gesemann et al.,(Gesemann et al., 1995). In contrast with a 45 kDa
1995). Individual G domains of agrin, namely G2A4, G2A0,C-terminal fragment of active agrinA4B8 (c45A4B8), which
c21B8, and c21B0, were synthesized as glutathioneconsists of the last two G domains, c21B8 no longer
S-transferase (GST) fusion proteins in Escherichia coli.bound to heparin, and AChR aggregation induced by
AChR-aggregating activity of c21B8 expressed in E. colithis fragment was not inhibited by heparin (Gesemann
was indistinguishable from c21B8 expressed in COS7et al., 1995). This shows that agrin-inducedAChR aggre-
cells (data not shown).gation per se is not inhibited by heparin. Because bind-
ing of rat agrin to a-dystroglycan is inhibited by heparin,
we speculated that the heparin-binding site in agrin may The Four Amino Acid Insert at Splice Site A
be identical to the site interacting with a-dystroglycan. Creates a Heparin-Binding Site
In the current study, we compared binding of agrin
Heparin inhibits both nerve- and agrin-induced AChR
isoforms to heparin, a-dystroglycan, and muscle cells
aggregation (Hirano and Kidokoro, 1989; Wallace, 1990;
to address the following questions. First, are the do-
Saito et al., 1993; Gesemann et al., 1995), suggestingmains in agrin that are required for heparin binding iden-
that heparin/HSPGs may be involved in agrin-inducedtical to those needed for a-dystroglycan binding? Sec-
AChR aggregation. The finding that heparin also inhib-ond, is binding of agrin to a-dystroglycan sufficient for
ited agrin binding to a-dystroglycan (Campanelli et al.,AChR aggregation, and if not, is it necessary to induce
1994; Gee et al., 1994; Sugiyama et al., 1994) suggestedAChR clusters? Third, do active agrin isoforms bind on
that agrin may bind to this peripheral membrane proteinmuscle cells to a site distinct from a-dystroglycan? We
via its heparin-binding site. As a consequence, bindingfind that the heparin-binding site of agrin maps to the
of agrin to a-dystroglycan would not be requisite forsecond G-like domain and that the 4 amino acid insert
AChR aggregation, since previous experiments haveat site A is necessary for binding. We show that both
shown that domains of agrinrequired for heparin bindingheparin-binding and AChR-aggregating activity of agrin
and those for AChR aggregation are distinct from eachisoforms do not correlate with their affinity to a-dystro-
other (Gesemann et al., 1995). The heparin-binding siteglycan. The agrin isoform agrinA0B0, which does not bind
characterized in these experiments is localized in theheparin and is inactive in AChR aggregation, binds
second G domain and/or the last EGF-like domain ofa-dystroglycan with high affinity; the agrin isoform ag-
the 45 kDa C-terminal fragment of agrinA4B8 (c45A4B8, seerinA4B8, which binds heparin and is active in AChR aggre-
gation, binds to a-dystroglycan with up to ten times Figure 1). To compare heparin and a-dystroglycan
Mechanism of Agrin-Induced AChR Aggregation
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Figure 2. The Four Amino Acid Insert at
Splice Site A Generates a Heparin-Binding
Site
(A) Autoradiogram of 7.5% SDS±poly-
acrylamide gel of immunoprecipitations with
anti-agrin antiserum. Conditioned medium of
35S-labeled COS cells, transfected with differ-
ent 95 kDa agrin constructs, was applied to
heparin columns. Lanes represent 35S-agrin
in conditioned medium (control), in the
flowthrough (Hep. 2), and in the eluate (Hep.
1) of the heparin columns.
(B) Autoradiogram of 12% SDS±poly-
acrylamide gel of purified, 125I-labeled G2 do-
main of agrin. Equal aliquots before heparin±
Sepharose (control), in the flowthrough (Hep.
2), and in the eluate (Hep. 1) of the heparin
columns were immunoprecipitated and re-
solved by SDS±PAGE. Molecular mass of
marker proteins in kilodaltons is shown.
binding of agrin, we aimed in a first set of experiments the 4 amino acid insert at site A would bind to this
to map the heparin-binding site of agrin. peripheral membrane protein. Results obtained by Sugi-
yama et al. (1994) with rat agrin suggest, however, thatHeparin-binding sites characterized in other proteins
affinities of agrinA4B8 and agrinA0B0 to a-dystroglycan areoften consist of clusters of basic amino acids that are
similar. Under the assumption that the binding of ratflanked by hydrophobic amino acids (Cardin and Wein-
agrin to heparin also requires the 4 amino acid insert attraub, 1989). In fibronectin, such clusters of basic amino
site A, these results suggest that the insert at site A isacids are essential for heparin binding (Barkalow and
Schwarzbauer, 1991). Within the region of chick agrin not required for the binding of agrin to a-dystroglycan.
that is required for heparin binding, there is one such To test this, we next measured binding of the 95 kDa
cluster of basic amino acids, the alternatively spliced C-terminal fragments of agrinA4B8 and agrinA0B0 to chick
insert at site A. To test the contribution of site A to skeletal muscle a-dystroglycan.
heparin binding, we passed 35S-labeled conditioned me- First, transfer overlay assays with partially purified
dium of COS7 cells that had been transiently transfected a-dystroglycan (Gee et al., 1993; Brancaccio et al., 1995)
with different agrin constructs over heparin±Sepharose were performed. To demonstrate that binding of agrin
columns. Flowthrough and eluate (0.5 M NaCl) of these isoforms was to a-dystroglycan, we probed fractions
columns were immunoprecipitated with anti-c95 agrin with iodinated laminin-1 (EHS-laminin). As shown in Fig-
antibodies and separated by SDS±polyacrylamide gel ure 3A, 125I-laminin-1 bound to a broad band of z180
electrophoresis (SDS±PAGE) as described (Gesemann kDa. The binding was Ca21 dependent and was abol-
et al., 1995). As shown in Figure 2A (left), c95A0B0 did not ished by 50 mg/ml heparin. These binding characteristics
bind to heparin±Sepharose, while c95A4B8 did bind. Since were indistinguishable from those reported for the bind-
these constructs differ by inserts at both sites A and B, ing of laminin-1 to a-dystroglycan from rabbit skeletal
we examined next which site influences heparin binding. muscle (Ibraghimov-Beskrovnaya et al., 1992; Ervasti
While c95A0B8 was not retained on the heparin column, and Campbell, 1993), providing strong evidence that the
c95A4B0 bound (Figure 2A, right), demonstrating that the observed binding is to chick a-dystroglycan. Next, we
4 amino acid insert at site A and not the insert at site
tested binding of 125I-c95A4B8 and 125I-c95A0B0. As shownB is required for heparin binding. This 4 amino acid
in Figure 3A (middle), 2.5 nM 125I-c95A0B0 bound to theinsert at site A was also required for heparin binding in
same band as laminin-1, whereas the same concentra-full-length chick agrin (data not shown). The fragment
tion of 125I-c95A4B8 gave only a very weak signal (right).G2A4 (see Figure 1) was sufficient for heparin binding,
Binding of 125I-c95A4B8, however, was readily detected atand its binding also depended on the 4 amino acid insert
25 nM (Figure 3A). As was observed for laminin-1, bind-at site A, as shown by the lack of binding of the fragment
ing of both agrin isoforms was Ca21 dependent (FigureG2A0 (Figure 2B). The peptide KSRK, which encodes the
3A; EDTA); 250 nM c95A0B0 competed binding of 125I-4 amino acid insert, however, was not sufficient, since
laminin-1, 125I-c95A4B8, and 125I-c95A0B0. These results show1 mM of this peptide did not compete with the binding
that laminin-1 and both agrin isoforms bind to identicalof agrinA4B8 to heparin columns (data not shown). Hence,
or nearby sites on chick a-dystroglycan. The bindingalthough the 4 amino acid insert at site A is required,
of laminin-1, c95A4B8, and c95A0B0 to a-dystroglycan inadditional amino acids in the G2 domain also contribute
membrane extracts of mouse C2C12 myotubes and toto form the heparin-binding site.
a-dystroglycan of bovine peripheral nerve was very simi-
lar to that observed for a-dystroglycan from chick skele-AChR-Aggregating Activity of Agrin Isoforms
tal muscle (data not shown; K. Matsumura, personalNegatively Correlates with Their
communication), indicating that species differences be-Affinity for a-Dystroglycan
tween a-dystroglycan do not greatly influence the bind-If the heparin-binding site of agrin were identical with
its a-dystroglycan-binding site, only agrin isoforms with ing of chick agrin isoforms. Our results are consistent
Neuron
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Table 1. Characteristics of Agrin Binding to a-Dystroglycan
% Binding
Competitor Added 125I-c95A0B0 125I-c95A4B8
mean 6 SEM mean 6 SEM
None 100.0 6 1.0 100.0 6 0.9
c95A0B0 (1 mM) 4.1 6 0.2 10.4 6 0.2
EDTA (10 mM) 0.4 6 0.2 6.6 6 0.7
Heparin (5 mg/ml) 94.5 6 0.3 54.6 6 0.3
Purified a-dystroglycan was immobilized on microtiter wells and
blocked with 2% FCS and 0.1% BSA. Wells were incubated with
either 1 nM 125I-c95A0B0 or 5 nM 125I-c95A4B8. Binding of both iodinated
fragments was set as 100%. Concentration of competitors was as
indicated. Each value represents the mean 6 SEM of six wells from
three independent experiments.
Since in transfer overlay assays a-dystroglycan is de-
natured and agrin binding could not be readily quanti-
fied, we established a solid-phase radioligand binding
assay. As seen by the nitrocellulose transfer overlay
method, c95A0B0 bound more strongly to a-dystroglycan
than c95A4B8. At 78 pM, the difference was z10-fold
(binding of c95A0B0/c95A4B8 5 10.6 6 2.7; mean 6 SEM;
n 5 5) and at 1.25 nM was z5-fold (binding of c95A0B0/
c95A4B8 5 4.6 6 0.6; mean 6 SEM; n 5 5; Figure 3B).
Hence, at ligand concentrations relevant for the AChR-
aggregating activity of c95A4B8, the agrin isoform that is
inactive in inducing AChR aggregates binds to native
a-dystroglycan more strongly than the active isoform.
Unlabeled c95A0B0 at a concentration of 1 mM inhibited
binding of both 125I-c95A0B0 and 125I-c95A4B8 to at least 90%
(Table 1), showing that both agrin isoforms bind to the
Figure 3. c95A0B0, Which Is Inactive in AChR Aggregation, Binds With
same sites on a-dystroglycan. The same concentrationHigher Affinity to a-Dystroglycan Than Active c95A4B8
of the low affinity ligand c95A4B8 was considerably less(A) Transfer overlay assays with a-dystroglycan from chick skeletal
efficient in competing binding of 125I-c95A0B0 and 125I-muscle. Proteins were separated on a 6% SDS±polyacrylamide gel,
c95A4B8 to a-dystroglycan (data not shown), indicatingblotted to nitrocellulose, and overlaid with iodinated laminin-1 or
agrin. that 1 mM c95A4B8 is not sufficient to saturate the available
Binding of 2.5 nM 125I-laminin-1 is abolished by 10 mM EDTA a-dystroglycan binding sites. As observed by others
(1 EDTA), 50 mg/ml heparin (1 Hep.), or 250 nM unlabeled c95A0B0 (Bowe et al., 1994; Gee et al., 1994; Campanelli et al.,
(1 c95A0B0). Binding of 2.5 nM 125I-c95A0B0 and 25 nM 125I-c95A4B8 is
1994; Sugiyama et al., 1994), binding of both agrin iso-Ca21 dependent (1 EDTA) and inhibited by 250 nM unlabeled c95A0B0
forms was Ca21 dependent (Table 1), but inhibition of(1 c95A0B0). Molecular mass of marker proteins in kilodaltons is
the binding by heparin differed between agrin isoforms.shown.
(B) Binding of c95A0B0 and c95A4B8 to chick a-dystroglycan. Purified Addition of 5 mg/ml heparin, a concentration sufficient
native a-dystroglycan was coated to microtiter plates, blocked by to prevent binding of 125I-laminin-1 to a-dystroglycan by
2% FCS, 0.1% BSA, and incubated with iodinated agrin isoforms. more than 60% (binding of 125I-laminin-1 in the presence
Background cpm (noncoated wells) was subtracted from each data
of 5 mg/ml heparin 5 36.7% 6 0.3%; mean 6 SEM;point. Data shown are the result of one representative experiment.
n 5 3), inhibited the binding of c95A4B8 by z50%, whileEach data point (mean 6 SEM) is the result of three wells. At low
only a weak inhibition of c95A0B0 binding was observedconcentrations (78 pM), active c95A4B8 binds in average with z10-
fold lower affinity to a-dystroglycan than inactive c95A0B0. Note that (Table 1). This is in agreement with the finding that the
half-maximal AChR-aggregating activity of c95A4B8 is reached at 35 4 amino acid insert at site A is required for heparin
pM (Gesemann et al., 1995). binding. At higher heparin concentrations (>50 mg/ml),
a-dystroglycan binding of c95A0B0 was partially inhibited
(data not shown), which may be due to unspecific, ionic
with those obtained by Sugiyama et al. (1994) who ob- interference of the polyanion heparin with the binding
served that both isoforms of rat agrin bound toT. califor- of c95A0B0 to a-dystroglycan.
nica and mouse a-dystroglycan. Hence, the 4 amino
acid insert required for heparin binding is not necessary
for the binding of chick agrin to a-dystroglycan. Most AChR-Aggregating Activity and Dystroglycan
importantly, our results show that c95A0B0, which is inac- Binding of Active Agrin Can Be Uncoupled
tive in AChR aggregation, binds to a-dystroglycan more The data presented so far make it unlikely that a-dys-
strongly than active c95A4B8. This shows that AChR-ag- troglycan is the signal-transducing receptor for agrin.
gregating activity of agrin isoforms does not correlate However, the low affinity binding of c95A4B8 to a-dystro-
glycan could still be necessary for its AChR-aggregatingwith their affinity to a-dystroglycan.
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activity. If AChR aggregation induced by agrin were in-
dependent of binding to a-dystroglycan, an agrin frag-
ment that does not bind a-dystroglycan but that is active
in inducing AChR aggregates might be found. Con-
versely, one might also expect to find a fragment of
active agrin that still binds a-dystroglycan after deleting
the domain responsible for AChR aggregation. To ap-
proach this, we measured binding to a-dystroglycan of
the minimal fragment required for AChR aggregation
(c21B8) and a deletion mutant of c95A4B8 that lacked the
21 kDa C-terminal end. The constructs lacking inserts
at sites A and B were always included as controls.
First, we tested binding of the deletion constructs,
called c95A0Dc21 and c95A4Dc21, to a-dystroglycan.
These constructs, with an Mr of 74 kDa, are similar to
the 70 kDafragments purified from basal lamina extracts
of the electric organ of T. californica that are inactive
in inducing AChR aggregates on cultured muscle cells
(Nitkin et al., 1987; Smith et al., 1992). As shown in Figure
4A, both 125I-labeled c95A0Dc21 and c95A4Dc21 bound to
native and denatured a-dystroglycan with similar affin-
ity, and more than 70% of their binding could be com-
peted by 1 mM unlabeled c95A0B0 (see legend to Figure
4A). This shows that fragments of chick agrin lacking
the domain required for the induction of AChR aggre-
gates are sufficient to bind a-dystroglycan. These re-
sults are reminiscent of those obtained by Ma et al.
(1993) who observed binding of the 70 kDa fragments
of T. californica agrin to postsynaptic membranes of the
electric organ. Subsequent purification has now shown
that this binding protein is most likely the T. californica
homolog to mammalian dystroglycan (Bowe et al., 1994; Figure 4. Domains Required for AChR Aggregation and for Binding
Deyst et al., 1995). to a-Dystroglycan Are Distinct
Next, we tested whether the minimal fragment re- Binding of different agrin truncations to a-dystroglycan was mea-
sured in a solid-phase radioligand binding assay as described inquired for AChR aggregation (Gesemann et al., 1995),
Experimental Procedures.c21B8, binds to a-dystroglycan. The concentrations of
(A) Binding of c95A0Dc21 and c95A4Dc21 to a-dystroglycan. Both 74125I-c21B8 and 125I-c21B0 (16 nM to 256 nM) were chosen kDa fragments bind equally well to a-dystroglycan. Most of the
in a range in which AChR-aggregating activity of c21B8 binding of 1 nM 125I-c95A0Dc21 and 125I-c95A4Dc21 is competed by
augments. As shown in Figure 4B, slight but significant 1 mM unlabeled c95A0B0 (c95A0Dc21, 15.8% 6 0.1%; c95A4Dc21,
binding was observed with 125I-c21B0. Approximately 28.9% 6 0.2%; mean 6 SEM; n 5 3). Inserts showthe corresponding
transfer overlay assays.75% of its binding was competed by 1 mM c95A0B0 (see
(B) Binding of c21B8, which is sufficient to induce AChR clusters,legend to Figure 4B), indicating that c21B0 binds weakly
and the inactive splice variant c21B0. Background (noncoated wells)to a-dystroglycan. In contrast with 125I-c21B0, only very
was subtracted from each data point. Data shown are the result ofhigh concentrations of 125I-c21B8 resulted in a few hun- one representative experiment. Each value represents the mean 6
dred counts. These counts were competed neither by SEM of three wells. Some binding is observed with c21B0 (125I-c21B0).
1 mM c95A0B0 nor by 4 mM unlabeled c21B8 (see legend The binding of 50 nM 125I-c21B0 can be competed by 1 mM c95A0B0
(24.2% 6 1.6%; mean 6 SEM; n 5 3), indicating that c21B0 bindsto Figure 4B), indicating that c21B8 does not bind to
with low affinity to a-dystroglycan. In contrast with this, the countsa-dystroglycan and that the few counts are due to un-
observed with 50 nM 125I-c21B8 cannot be competed by 4 mM unla-specific binding. In summary, these data show that the
beled c21B8 (106.6% 6 6.0%; mean 6 SEM; n 5 6) or by the a-capability of inducing AChR aggregation (c21B8) and of dystroglycan-binding c95A0B0 at 1 mM (111.0% 6 8.3%; mean 6
binding to a-dystroglycan (c95A4,0Dc21) can be uncou- SEM; n 5 6). Hence, the few counts at very high concentrations of
pled. Therefore, this is strong evidence that binding of 125I-c21B8 are most likely unspecific. Note that half-maximal AChR-
aggregating activity of c21B8 is reached at 13 nM (Gesemann et al.,agrinA4B8 to a-dystroglycan is not necessary to induce
1995).AChR aggregation.
Agrin Fragments That Are Active in AChR also express a-dystroglycan; therefore, one would ex-
pect that the inactive deletion of c95A4B8, namelyAggregation Bind to a Novel Site
on Muscle Cells c95A4Dc21, would also bind to muscle cells. As shown
in Figure 5A, binding of c95A0Dc21 and c95A4Dc21 toSeveral lines of evidence suggest that AChR-aggregat-
ing activity of agrin is mediated by a signal-transducing chick myotubes was indeed very similar to their binding
to purified a-dystroglycan (see Figure 4A). Approxi-receptor on muscle cells (McMahan, 1990). Conse-
quently, c21B8, which is active in AChR aggregation, mately 80% of the binding of 125I-c95A0Dc21 and 125I-
c95A4Dc21 was inhibited by 1 mM unlabeled c95A0B0 (seeshould bind specifically to muscle cells. Chick myotubes
Neuron
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than 40% with 1 mM unlabeled c95A0B0, but they were
not lowered with 4 mM unlabeled c21B8 (see legend to
Figure 5B). This suggests that some of the binding of
c21B0 to muscle cells is due to its weak binding to
a-dystroglycan. Although 1 mM c95A0B0 saturates all the
a-dystroglycan-binding sites available on chick myo-
tubes (see below), the competition of 125I-c21B0 was only
partial, suggesting that the remaining counts are most
likely due to nonspecific binding (see below). The signifi-
cant binding of 125I-c21B8 to muscle cells was not inhib-
ited by 1 mM c95A0B0, but was inhibited by z65% with 4
mM unlabeled c21B8 (see legend to Figure 5B). In con-
junction with the binding data on purified a-dystrogly-
can, these experiments are strong evidence that c21B8,
the agrin fragment that is active in inducing AChR aggre-
gation, binds to a novel site on muscle cells that is not
a-dystroglycan.
Agrin-Binding Proteins and AChR Aggregation
We have documented earlier that induction of AChR
aggregates by c21B8 requires concentrations more than
300 times higher than those of c95A4B8 (Gesemann et al.,
1995). Since c21B8 binds neither to heparin (Gesemann
et al., 1995) nor to a-dystroglycan (see Figure 4), its
lowered AChR-aggregating activity may be due to the
lack of any of these binding sites. Alternatively, c21B8
may bind to the putative signal-transducing receptor
with lower affinity than c95A4B8 for structural reasons.
To see to what extent binding to heparin or to
a-dystroglycan (or to both) contributes to the AChR-
aggregating activity of agrin, we asked whether agrin
fragments, which bind toone of the two binding partners
but are inactive in aggregating AChRs, would influence
Figure 5. Active Agrin Binds to a Novel Site on Cultured Myotubes
AChR aggregation induced by c95A4B8. No difference inThat Is Distinct from a-Dystroglycan
the dose-response curve was observed in the presenceCultured chick myotubes were incubated for 30 min with iodinated
of 2 mM of the heparin-binding G2A4 fragment (data notagrin fragments at the concentrations indicated. Bound radioactivity
shown). In contrast with this, 200 nM c95A0B0 shifted thewas determined as described in Experimental Procedures. Data
shown are the results of one representative experiment. Each value dose-response curve for AChR aggregation 2- to 3-fold
represents the mean 6 SEM of three dishes. to higher concentrations (Figure 6A). This concentration
(A) Binding of c95A0Dc21 and c95A4Dc21, lacking the most C-terminal of c95A0B0 is sufficient to saturate all the a-dystroglycan-
21 kDa, to chick muscle cells. Binding is similar to that observed on binding sites available on chick myotubes (binding of
purified a-dystroglycan (compare Figure 4A). As on a-dystroglycan,
640 pM 125I-c95A0B0 in the presence of 200 nM unlabeledbinding of 1 nM iodinated ligand was competed by 1 mM c95A0B0
c95A0B0: 2.8% 6 0.5%; mean 6 SEM; n 5 5). Thus,binding(c95A0Dc21, 11.8% 6 1.3%; c95A4Dc21, 20.0% 6 0.4%;mean 6 SEM;
of c95A4B8 to a-dystroglycan seems to support its AChR-n 5 4).
(B) Binding of the 21 kDa fragment of active agrin (125I-c21B8) and its aggregating activity. However, the lack of binding to
inactive counterpart (125I-c21B0). Unlike binding to purified a-dystro- a-dystroglycan cannot explain the z300-fold lower
glycan (Figure 4B), 125I-c21B0 binds less strongly than 125I-c21B8. Bind- AChR-aggregating activity of c21B8.
ing of 50 nM 125I-c21B0 is affected by 1 mM c95A0B0 (56.4% 6 6.3%; To test whether a reduced affinity of c21B8 for themean 6 SEM; n 5 4), but not by 4 mM c21B8 (96.7% 6 3.7%; mean putative signal-transducing receptor may be the reason
6 SEM; n 5 4). Hence, binding of c21B0 to muscle cells is partially
for its lowered AChR-aggregating activity, the efficiencydue to its binding to a-dystroglycan. Binding of 25 nM 125I-c21B8 is
of c21B8 and c95A4B8 to compete binding of 125I-c21B8 onnot inhibited by 1 mM c95A0B0 (96.7% 6 3.7%; mean 6 SEM; n 5 4),
but is inhibited by 4 mM unlabeled c21B8 (34.6% 6 1.3%; mean 6 cultured myotubes was measured. While z500 nM c21B8
SEM; n 5 4). These data indicate that muscle cells express a mole- was needed for half-maximal inhibition, z12 nM c95A4B8
cule distinct from a-dystroglycan that specifically binds c21B8. was sufficient (Figure 6B). Competition with both active
ligands, however, was incomplete (maximum of z65%),
suggesting that the remaining counts were due to non-
specific binding. Indeed, counts in the same range were
legend to Figure 5A), indicating that they bind to measuredwhen 125I-c21B8 was incubated on empty, gela-
a-dystroglycan. tin-coated tissue culture dishes (data not shown). The
Binding of 125I-c21B0 and 125I-c21B8 to muscle cells was z40 times higher efficiency of c95A4B8 to bind to muscle
clearly different from their binding to purified a-dystro- cells indicates that the majority of the difference in the
glycan. As shown in Figure 5B, c21B0 bound only weakly efficacy to induce AChR aggregation is based on a de-
to muscle cells, while c21B8 bound more strongly. The creased affinity of c21B8 to the putative signal-transduc-
ing receptor. Binding of 125I-c21B8 was not competed bycounts observed with 125I-c21B0 were inhibited to more
Mechanism of Agrin-Induced AChR Aggregation
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Figure 7. Binding Sites for c95A4B8 and c95A0B0 Are Differently Distrib-
uted on Cultured C2C12 Myotubes
AChR aggregates were induced by low concentrations of c95A4B8
for 12 hr. Live cells were then further incubated with medium (A and
B), 20 nM c95A0B0 (C and D), or 20 nM c95A4B8 (E and F). AChRs,
visualized by rhodamine-a-bungarotoxin (A, C, and E). Muscle cell±
bound agrin, visualized as described in Experimental Procedures
(B, D, and F). No staining of endogenous mouse agrin or c95A4B8
used to induce AChR clusters is seen in control cultures (B). Incuba-
tion with c95A0B0 results in a bright signal for muscle cell±bound
c95A0B0 (D). Some of the AChR clusters contain a higher density of
c95A0B0-binding sites, while in other clusters, no accumulation is
seen (arrows). In contrast, muscle cell±bound c95A4B8 (F) colocalizes
with all AChR clusters (compare E and F). Scale bar represents 50
mm.
agrin isoform may also be reflected by a difference in
the distribution of the binding sites on muscle cells. We
therefore looked at their distribution in cultured C2C12
Figure 6. Diminished AChR-Aggregating Activity of c21B8 Is cells (Yaffe and Saxel, 1977). Because of the greatlyMatched by Its Lowered Affinity for the Putative Agrin Receptor and
diminished affinity of c21B8 for the putative agrin recep-the Loss of Binding to a-Dystroglycan
tor, the 95 kDa fragments were used. A similar experi-(A) Binding to a-dystroglycan facilitates agrin-induced AChR aggre-
ment has been reported by Nastuk et al. (1991) whogation. Dose-response curves for c95A4B8 (closed squares, control)
determined the distribution of agrin purified from T. cali-and in the presence of 200 nM c95A0B0 (open circles, 1 c95A0B0). This
concentration of c95A0B0 saturates free binding sites of a-dystrogly- fornica. Because the protein preparations used in their
can and reduces the apparent concentration of c95A4B8 by z50%. studies contained a mixture of fragments from several
Data points are means 6 SEM of two dishes, where AChR clusters agrin isoforms (Nitkin et al., 1987; Smith et al., 1992),
of at least 20 myotube segments were counted in each dish (see
no conclusions regarding the distribution of the signal-Experimental Procedures). One representativeexperiment is shown.
transducing receptor can be drawn. In our experiments,Dotted lines indicate background level, half-maximal, and maximal
we used individual recombinant agrin isoforms. To seeresponse in AChR aggregation. Curves were fit to data by eye.
(B) Cultured chick myotubes were incubated for 30 min with 25 whether the binding sites codistribute with AChR clus-
nM 125I-c21B8 in the presence of unlabeled agrin fragments at the ters, we induced C2C12 myotubes to form such clusters
concentrations indicated. Bound radioactivity was determined as with low concentrations of c95A4B8. AChRs were visual-
described in Experimental Procedures. While z500 nM c21B8 was ized with rhodamine-labeled a-bungarotoxin (Figures
needed for half-maximal inhibition, z12 nM c95A4B8 was sufficient.
7A, 7C, and 7E). Subsequently, cells were incubatedData represent results of two independent experiments with two
with 20 nM c95A4B8 or c95A0B0, and muscle cell±bounddishes in each. Curves were fit to data points by eye. Each value
agrin was visualized by anti-c95 agrin antibodies andrepresents the mean 6 SEM of four dishes. Note that z35% of
the binding of 125I-c21B8 cannot be competed by any fragments, appropriate secondary reagents. No staining of endoge-
indicating nonspecific interactions. Dotted lines indicate maximal, nous mouse agrin or of c95A4B8 used to induce AChR
half-maximal inhibition, and 100% binding. clusters was observed (Figure 7B). Incubation with 20
nM c95A0B0 yielded a bright signal (Figure 7D). Since
1 mM c95A0B0 or 4 mM c21B0 (Figure 6B), which shows c95A0B0 binds strongly to a-dystroglycan, this staining
that only agrin isoforms that induce AChR aggregation most likely reflects the distribution of this peripheral
bind to the receptor recognized by c21B8. membrane protein. As shown in Figures 7C and 7D, in
The different binding characteristics of agrin isoforms some of the AChR clusters (arrows)agrin-like immunore-
activity was not accumulated. Colocalization of c95A0B0that are active in AChR aggregation and the inactive
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and AChR clusters was found in 55% 6 2.3% (mean 6
SEM with n 5 10 tissue culture dishes; total of 801
clusters) of the cases. There was no significant differ-
ence in the degree of colocalization when AChR aggre-
gates were located at the edge (59% 6 2.6%) or inside
of a myotube (52% 6 3.5%). The accumulation of muscle
cell±bound c95A0B0 in AChR clusters is consistent with
a-dystroglycan and other components of the DGC being
concentrated in AChR aggregates in vitro (Gee et al.,
1994; Campanelli et al., 1994; Sugiyama et al., 1994;
Cohen et al., 1995). Muscle cell±bound c95A4B8 showed
an even higher degree of colocalization with AChR ag-
gregates under our assay conditions (Figure 7F). In this
case, 96% 6 1.4% (mean 6 SEM with n 5 5 tissue
culture dishes; total of 446 clusters tested) of the AChR
aggregates stained brightly with anti-agrin antibodies.
Hence, the existence of an additional binding site in
c95A4B8 is also reflected by a difference in the distribution Figure 8. Binding Partners and Location of Their Binding Domains
of binding sites on cultured myotubes. in the 95 kDa Fragments of AgrinA4B8 and AgrinA0B0
c95A4B8 (active in AChR aggregation) binds to a-dystroglycan, hepa-
rin, and the putative agrin receptor. In contrast, c95A0B0 (inactive inDiscussion AChR aggregation) binds only to a-dystroglycan. The binding of
c95A0B0 to a-dystroglycan is up to ten times stronger than the binding
Agrin is a large, multidomain molecule of the extracellu- of c95A4B8. Note also the difference between heparin binding and a-
dystroglycan binding: heparin binding requires the 4 amino acidlar matrix whose best characterized function to date is
insert at site A, and the G2A4 fragment is sufficient for this binding.to induce the formation of postsynaptic specializations
In contrast with this, a-dystroglycan binding does not depend onin muscle fibers. This activity is contained in the 95 kDa
the 4 amino acid insert and the G2 domain is not sufficient for high
C-terminal part of the molecule and is strongly affected affinity binding (data not shown). Structural domains are indicated
by alternative mRNA splicing (Nitkin et al., 1987; Tsim by boxes (compare also Figure 1).
et al., 1992; Ferns et al., 1993; Gesemann et al., 1995).
Since the focus of this study was to elucidate the mecha- binding affinity between c95A0B0 and c95A4B8 is also foundnisms underlying the synaptic activity of agrin, we have with a-dystroglycan from chicken heart, mouse C2C12
now characterized some of the binding partners of this myotubes, and bovine sciatic nerve (unpublished data).
95 kDa agrin fragment. We find that c95A4B8, which is It is therefore conceivable that binding of agrinA0B0 tohighly active in inducing AChR aggregation, binds to at
a-dystroglycan may help stabilizing the integrity of the
least three molecules, namely heparin, a-dystroglycan, tissue in a manner similar to that proposed for laminin.
and a novel site on muscle cells that most likely repre- Consequently, binding of agrinA0B0 to a-dystroglycansents the signal-transducing receptor for agrin (Figure may compensate for the loss of laminin and so lessen
8). In contrast with this, c95A0B0, which is inactive in AChR the severity of some muscular dystrophies (for review
aggregation, binds neither heparin nor the putative sig- see Campbell, 1995).
nal-transducing receptor for agrin, but instead binds Interestingly, the agrin isoform agrinA0B0 is expressed
strongly to a-dystroglycan (Figure 8). very early in the developing spinal cord and only later,
when neurons differentiate, sequences at sites A and B
are inserted to create an agrin isoform that binds muchAgrin Expressed by Non-Neuronal Cells
Binds a-Dystroglycan less to a-dystroglycan, but concomitantly becomes
functional in inducing aggregation of AChRs (McMahanThe finding that agrinA0B0, which is inactive in AChR ag-
gregation, binds a-dystroglycan more strongly than et al., 1992; Ma et al., 1995; L. S. Honig, M. J. Werle,
S. E. Horton, and M. A. R., unpublished data). Hence,agrinA4B8 provides evidence for a physiological role of
this agrin isoform. Transcripts encoding agrinA0B0 are the strong binding of agrin to a-dystroglycan may be
important early in neural development, while the residualhighly expressed in non-neuronal tissue (e.g., muscle,
sciatic nerve, heart, and kidney; Ruegg et al., 1992; a-dystroglycan binding of the active agrin isoform may
have little significance in the formation of the NMJ (seeMcMahan et al., 1992; Hoch et al., 1993; Ma et al., 1994).
All these tissues are also positive for agrin-like immuno- below).
reactivity (Reist et al., 1987; Godfrey et al., 1988; Fallon
and Gelfman, 1989; Rupp et al., 1991; Godfrey, 1991; Role of Heparin and a-Dystroglycan
Binding in AChR AggregationHoch et al., 1993), and they also express a-dystroglycan
(Ibraghimov-Beskrovnaya et al., 1992; Yamada et al., We show that the heparin-binding site of agrin requires
the alternatively spliced insert (Lys-Ser-Arg-Lys) at site1994; Durbeej et al., 1995). The 95 kDa C-terminal frag-
ment of chick agrinA0B0 binds a-dystroglycan from the A (Figure 2). The sequence of this insert is identical in
the marine ray, rat, and mouse (Rupp et al., 1991, 1992;bovine sciatic nerve, and agrin-like immunoreactivity
colocalizes with a-dystroglycan in the outermost layer Smith et al., 1992), suggesting that the function to bind
heparin is conserved across species. Alternative splic-of the myelin sheaths (K. Matsumura, personal commu-
nication). In addition, the up to 10-fold difference in ing of agrin transcripts at sites A and B is coordinated
Mechanism of Agrin-Induced AChR Aggregation
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such that isoforms with inserts at site B always contain the size and shape of the AChR clusters was seen (un-
published data). In addition, the size of AChR clustersthe 4 amino acid insert at site A (Ruegg et al., 1992;
Hoch et al., 1993). Hence, agrin isoforms synthesized induced by the non-dystroglycan-binding c21B8 does not
differ from those induced by c95A4B8 (unpublished data).by neurons contain the 4 amino acid insert (McMahan
et al., 1992; Ma et al., 1995; L. S. Honig, M. J. Werle, These results suggest that the size of the AChR aggre-
gates is not influenced by the interaction of neural agrinS. E. Horton, and M. A. R., unpublished data) and conse-
quently bind heparin. Binding of heparin abolishes the with a-dystroglycan.
The slight inhibition of agrin-induced AChR aggrega-AChR-aggregating activity of agrin (Wallace, 1990), un-
less the nonheparin binding fragment c21B8 is used to tion by c95A0B0 may also explain why Gee et al. (1994)
observed inhibition of agrin-induced AChR aggregationinduce AChR aggregation (Gesemann et al., 1995). Bind-
ing of heparin to the G2 domain of agrin may prevent the with MAb IIH6. This antibody, like c95A0B0, blocks the
binding of agrin to a-dystroglycan. In these experiments,interaction of agrin either with heparin-like molecules or
with the putative signaling receptor. We favor the sec- the amount of agrin used to induce AChR aggregation
was so little that a slight shift in the dose-responseond possibility because even a 50,000-fold excess of
the heparin-binding domain G2A4 does not affect AChR- relation may have resulted in an apparently complete
block of AChR aggregation. On the other hand, the fail-aggregating activity of c95A4B8 and the nonheparin-bind-
ing fragment c95A0B8 has similar AChR-aggregating ac- ure of Sugiyama et al. (1994) to observe inhibition could
be due to higher concentrations of active agrin used fortivity as c95A4B8 (unpublished data; see also Ferns et al.,
1993). the induction of AChR clusters.
The binding of agrin to a-dystroglycan seems not toThe concentration of c21B8 required to induce half-
maximal AChR clustering (EC50) is z13 nM, while the play a role in transferring a signal for AChR aggregation
to the inside of the muscle cells. We propose that it mayEC50 of c95A4B8 is z35 pM (Gesemann et al., 1995). How
can our data explain this difference in activity? In previ- rather have a structural role in AChR aggregation. The
finding that rapsyn (previously called 43 kDa protein)ous work, we speculated that the difference may be
based on the loss of binding of c21B8 to a helper protein. links dystroglycan and AChRs when transiently ex-
pressed in quail fibroblasts (Apel et al., 1995) has pro-As candidates for such a helper, we proposed a-dys-
troglycan or HSPGs (or both). This suggestion was also vided evidence for such a role. Association of AChRs
with the DGC via rapsyn may attach AChRs to the cy-based on the observation that myogenic cell lines with
a deficiency in glycosaminoglycan synthesis are less toskeleton and hence be necessary for the formation of
clusters. Consistent with this, muscle fibers that areresponsive to active agrin isoforms (Ferns et al., 1992,
1993; Gordon et al., 1993). Consistent with the idea that deficient in rapsyn fail to form AChR clusters in vivo and
in response to agrin in vitro,and there isno accumulationa-dystroglycan is the cause for this difference in effi-
cacy, these cell lines express a-dystroglycan that binds of the DGC at the NMJ in vivo (Gautam et al., 1995).
agrin less efficiently (Campanelli et al., 1994; Sugiyama
et al., 1994). We have now specifically looked at the
Mechanism of Agrin-Inducedpossibility of a-dystroglycan being a helper protein by
AChR Aggregationmeasuring AChR aggregation induced by c95A4B8 in the
Our data indicate that the difference in AChR aggrega-presence of 200 nM of inactive c95A0B0, a concentration
tion between agrin isoforms is based on the affinity withthat is sufficient to block all the a-dystroglycan-binding
which they bind to a novel site on muscle cells. Thissites on the myotubes. We observed a 2- to 3-fold shift
site most likely represents the long sought signal-trans-of the dose-response curve to higher concentrations
ducing receptor for agrin for the following reasons: bind-(Figure 6A), indicating that the lack of the binding site
ing to this site is selective for agrin fragments that arefor a-dystroglycan in c21B8 accounts only for an approxi-
active in inducing AChR aggregates (Figure 6B) andmately 3-fold loss in AChR-aggregating activity. It is
binding to this site on C2C12 muscle cells also inducestherefore unlikely that the weaker binding of agrin to
phosphorylation of the b subunit of AChRs (T. Meiera-dystroglycan expressed in these GAG-deficient cells
and B. G. Wallace, personal communication). The recentis the molecular basis for their decreased respon-
identification of neuroligin 1, a ligand that is only recog-siveness to agrin.
nized by one specific isoform of the b-neurexins (Icht-Our results, however, are compatible with a role of
chenko et al., 1995), has demonstrated that alternativea-dystroglycan in binding neural agrin locally to the sur-
splicing can be a means to regulate specificity of ligand±face of the muscle cell. The aggregation of the DGC at
receptor interactions. Agrin isoforms are an additionalagrin-induced AChR clusters (Campanelli et al., 1994;
example for such a mechanism.Gee et al., 1994; Sugiyama et al., 1994; Cohen et al.,
The competition experiments indicate that most of1995) increases the number of agrin-binding sites. As
the loss of the AChR-aggregating activity of c21B8 is dueproposed by Cohen et al. (1995), this would allow the
to its diminished affinity to the putative agrin receptorbinding of additional neural agrin at AChR clusters and,
(Figure 6B). This implies that high affinity binding of agrinconsequently, small clusters could become bigger. This
to this receptor involves sequences N-terminal to themodel would be consistent with the observation that
last G domain. This is supported by the findings thatthe anti-a-dystroglycan MAb IIH6, which blocks binding
splicing at site A affects AChR aggregation (while solu-of agrin, affects the shape of agrin- and nerve-induced
ble agrinA4B0 has some AChR aggregating at high con-AChR clusters (Campanelli et al., 1994; Cohen et al.,
centrations, agrinA0B0 is inactive [Ferns et al., 1993; Gese-1995). However, when we blocked binding of c95A4B8 to
a-dystroglycan with an excess of c95A0B0, no effect on mann et al., 1995]) and that MAbs directed against the
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Skeletal muscle a-dystroglycan was purified either by DEAE chro-G2 domain in rat agrin block its AChR-aggregating activ-
matography followed by a WGA affinity column or on a lamininity (Hoch et al., 1994).
fragment E3 affinity column as described by Brancaccio et al. (1995).We do not yet know the nature of the muscle cell
Membraneproteins of C2C12myotubes were prepared as described
receptor that recognizes only active agrin. The finding by Campanelli et al. (1994).
that c21B8 also induces tyrosine phosphorylation of the
b subunit of the AChR in C2 myotubes (T. Meier and Agrin Expression Constructs
Numbering of oligonucleotides is according to the sequence pub-B. G. Wallace, personal communication) suggests that
lished by Tsim et al. (1992). All PCR products used to generateit may belong to the family of receptor tyrosine kinases,
expression constructs were sequenced to ensure that no mutationssuch as the recently described muscle-specific receptor
were introduced by DNA amplification. Constructs encoding iso-
tyrosine kinase, MuSK, that accumulates at the NMJ forms lacking the C-terminal 21 kDa of agrin were constructed as
(Jennings et al., 1993; Valenzuela et al., 1995). Alterna- follows. Pc95A4,0Dc21 were generated by PCR using either pc95A4B11
tively, the agrin receptor might activate such proteins or pc95A0B0 as template together with the oligonucleotides
EcoRI_s4649 (AGC TTG AAT TCG GAG CAG GAC CAC ACC A) andvia an intracellular signaling mechanism.
the antisense primer as5350_stop_XbaI (CCG GGT CTA GAT CACOther possible candidates also include proteins rec-
TCT GCA TCT CCA GCT GC). The PCR product was gel purified,ognized by N-acetylgalactosamine (GalNac)-specific
digested with ClaI and XbaI, and inserted into pc95A4B11 to yieldlectins. They are concentrated at NMJs in vivo (Scott et pc95A0Dc21 or pc95A4Dc21.
al., 1988) and at AChR clusters invitro (Martin and Sanes, Bacterial expression constructs for individual G domains were
1995). Moreover, the GalNac-specific lectin Vicia Villosa constructed as follows. pc21B8 and pc21B0 were generated by PCR
using pc95A4B8 and pc95A0B0 as template with the oligonucleotidesagglutinin B4 (VVA-B4) potentiates AChR-aggregating
BamHI_s5353 (CCC GGA TCC GCT GGA GAT GCA GAG) andactivity of rat agrin (Martin and Sanes, 1995). A receptor
as6146_XbaI (CCG GGT CTA GAC TTG GTT CAA GGT TT). The PCRwhose affinity for agrin depends on its sugar moieties
product was gel purified, subcloned into PCR II vector (Invitrogen),
may explain the differences in agrin responsiveness of digested with BamHI and EcoRI, and inserted into theBamHI±EcoRI-
the myogenic cell lines that are deficient in carbohydrate digested expression vector PGEX-2t (Pharmacia). Constructs en-
synthesis (Ferns et al., 1992, 1993; Gordon et al., 1993). coding the second G domain of agrin, pG2A0 and pG2A4, were gener-
ated by PCR using pc95A0B0 and pc95A4B8 as template and the primersOur data suggest that sites in agrin that are involved
BamHI_s4651 (GT CCC GGA TCC GAG CAG GAC CAC ACC ATG)in its binding to a-dystroglycan and those that bind to
and as5195 (GGC CCT CTA GAC TAT TGG ATC CTG AAA GTG GAGthe putative signaling receptor are close together. This
ATT TCA ACG G). PCR products were purified from agarose gel,
raises the possibility that another member of the DGC subcloned into PCR II vector, digested with BamHI and EcoRI, and
may be the putative receptor for active agrin (for review inserted into PGEX-2t.
see Apel and Merlie, 1995). We have now generated the
tools that enable us to distinguish binding of active agrin Labeling of Agrin
35S labeling of recombinant agrin fragment expressed in COS andto the different binding partners on muscle cells, which
293 cells was done as previously described (Gesemann et al., 1995).will facilitate the identification of this signal-transducing
Iodinations of agrin fragments were done by the chloramin T methodreceptor.
described by Hunter and Greenwood (1962) with minor modification.
The labeling reaction was carried out with 20±100 mg of protein
dissolved in TBS, and the protein solution was supplemented withExperimental Procedures
100 ml of 0.5 M potassium-phosphate buffer (pH 7.0). After adding
0.5 to 1 mCi of Na-[125I] (New England Nuclear±DuPont), the labelingCell Culture and Transfection
reaction was started with 10 ml of a chloramin T solution (2 mg/mlPrimary chick myotubes or myotubes from the mousecell line C2C12
chloramin T dissolved in 0.05 M K-phosphate buffer [pH 7.0]). Afterwere prepared as previously described (Gesemann et al., 1995).
45 s, the labeling reaction was stopped with 10 ml of 2 mg/ml Na2S2O5Transfection of COS or 293 cells were carried out as described by
in 0.05 M K-phosphate buffer (pH 7.0). Free 125I was separated fromGesemann et al. (1995).
labeled proteins by gel filtration with G25-Sepharose (Pharmacia).
Columns were equilibrated and eluted with MEM (GIBCO), 20 mM
HEPES (pH 7.2) (H-MEM), 0.1% bovine serum albumin (BSA), 100Purification of Agrin and a-Dystroglycan
U/ml penicillin, and 100 mg/ml streptomycin. More than 80% of theAgrin isoforms expressed in COS or 293 cells were purified with
protein was recovered after gel filtration. Radioactivity incorporatedMAb 5B1 affinity columns as previously described (Gesemann et
per microgram of protein was determined by separating knownal., 1995). Individual domains of agrin were expressed as GST fusion
amounts of protein by SDS±PAGE and quantitation with a phospor-proteins in bacteria. Purification was as follows. Overnight cultures
imager. In the binding curves of each individual experiment, countsof E. coli (JM-109) transformed with the recombinant expression
for different agrin fragments were corrected for differences in incor-vector PGEX-2t (Pharmacia) were diluted 1:100 in fresh LB medium
poration of 125I. Note that therefore only values within one individualcontaining 50 mg/ml ampicillin and grown at 378C until OD600 reached
experiment can be compared with each other, but not between0.8. Fusion proteins were then induced by adding IPTG to a final
different experiments. The biological activity of all active agrin frag-concentration of 0.5 mM, and cells were grown for an additional
ments was retained after iodination as measured by their ability to5±6 hr. Cells were pelleted and resuspended in 1/100 culture volume
induce AChR clusters on cultured chick myotubes.of PBS, lysed on ice by mild sonication, and centrifuged at 39,000
3 g for 20 min at 48C. The supernatant was loaded onto a 2 ml
glutathione±Sepharose 4B column (Pharmacia) and washed with Solid-Phase Radioligand Binding Assay
a-Dystroglycan was immobilized on microtiter plates by incubation10±20 bed volumes of PBS. The fusion protein was eluted with 10
ml of freshly prepared 10 mM reduced glutathione in 50 mM Tris±HCl overnight at 48C in 50 mM sodium carbonate (pH 9.6). Remaining
binding sites were saturated by incubation with TBS, 2% fetal calf(pH 8.0). Eluates were dialyzed versus 50 mM Tris±HCl (pH 8.5), 150
mM NaCl. CaCl2 was then added to a final concentration of 2.5 mM, serum, 1 mg/ml BSA. After three washes with TBS containing 1.25
mM CaCl2 and 1 mM MgCl2 (TBS1Ca/1Mg), 125I-agrin fragments wereand proteins were subjected to thrombin digestion for 1±2 hr at
room temperature. The digested protein was reloaded on the gluta- added and incubated at room temperature for 3 hr in TBS1Ca/1Mg
containing 3% BSA. The plates were washed four times withthione±Sepharose 4B column, and the flowthrough was collected.
Recombinant agrin fragments were analyzed by SDS±PAGE, and TBS1Ca/1Mg, and bound radioactivity in each well was counted with
a gamma counter.the concentration was determined by the Bio-Rad DC protein assay.
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Transfer Overlay Assays and the agrin-binding dystrophin-associated glycoprotein complex.
Neuron 15, 115±126.Purified skeletal muscle a-dystroglycan or C2C12 membrane ex-
tracts were treated with reducing SDS sample buffer, separated by Barkalow, F.J., and Schwarzbauer, J.E. (1991). Localization of the
6% SDS±PAGE (Laemmli, 1970), and transferred to nitrocellulose major heparin-binding site in fibronectin. J. Biol. Chem. 266, 7812±
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